CoChat

The Cardiovascular Effects of GLP‐1 Receptor Agonists

Open access
Okerson, Theodore, Chilton, Robert J. · 2012 · Cardiovascular Therapeutics
Cited by 136

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

SUMMARY: Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety. GLP‐1 receptors have also been identified in the heart, kidneys, and blood vessels, leading to the hypothesis that GLP‐1R agonists may affect cardiovascular function or cardiovascular disease (CVD). The aim of this literature review was to assemble and assess preclinical and clinical data of potential medical importance regarding the cardiovascular effects of GLP‐1R agonists. Preclinical studies with the GLP‐1R agonists GLP‐1, exenatide, or liraglutide provided evidence that GLP‐1R stimulation favorably affects endothelial function, sodium excretion, recovery from ischemic injury, and myocardial function in animals. Similar observations have been made in exploratory studies on GLP‐1 infusion in normal subjects and patients with type 2 diabetes. Post hoc analyses of phase III studies of patients with type 2 diabetes treated with exenatide(bid or qw) or liraglutide(qd) showed that these GLP‐1R agonists reduced blood pressure, an effect largely independent of weight loss, and that liraglutide slightly increased heart rate. Preliminary data also indicated that GLP‐1R agonists reduced markers of CVD risk such as C‐reactive protein and plasminogen activator inhibitor‐1. Ongoing studies are examining the effects of administering GLP‐1R agonists to patients at risk of CVD, postangioplasty patients, post‐CABG patients, and patients with heart failure. Additional studies should provide meaningful data to determine whether GLP‐1R agonists provide unique treatment benefits to patients at risk for or with established CVD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5922.2010.00256.x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 136

Metadata

Authors
Okerson, T., & Chilton, R. J.
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2010-12-19
Volume
30
Issue
3
Pages
e146-55
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W1526784932
Cited by
136
References
25
FWCI
6.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Cardiovascular Effects of GLP‐1 Receptor Agonists. https://app.cochat.ai/papers/10.1111/j.1755-5922.2010.00256.x
The paper
Okerson, T., & Chilton, R. J. (2012). The Cardiovascular Effects of GLP‐1 Receptor Agonists. Cardiovascular Therapeutics. https://doi.org/10.1111/j.1755-5922.2010.00256.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.